Key Points
Question
Is administration of IL-6 antagonists associated with 28-day all-cause mortality in patients hospitalized for COVID-19?
Findings
This prospective meta-analysis of 27 randomized trials included 10 930 patients, of whom 2565 died by 28 days. The 28-day all-cause mortality was lower among patients who received IL-6 antagonists compared with those who received usual care or placebo (summary odds ratio, 0.86). The summary odds ratios for the association of IL-6 antagonist treatment with 28-day all-cause mortality were 0.78 with concomitant administration of corticosteroids vs 1.09 without administration of corticosteroids.
Meaning
Administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality in patients hospitalized for COVID-19.
Abstract
Importance
Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm.
Objective
To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.
Data Sources
Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts.
Study Selection
Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria.
Data Extraction and Synthesis
In this prospective meta-analysis, risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I2 statistic. The primary analysis was an inverse variance–weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality.
Main Outcomes and Measures
The primary outcome measure was all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days.
Results
A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P = .003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P < .001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P = .52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16).
Conclusions and Relevance
In this prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.
Trial Registration
PROSPERO Identifier: CRD42021230155
This prospective meta-analysis estimates the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.
Introduction
Excessive systemic inflammation and raised IL-6 levels resulting from dysregulated host immune responses1,2,3 are associated with adverse clinical outcomes in patients hospitalized with COVID-19.4 This led to the design of several randomized clinical trials assessing the efficacy of IL-6 antagonists in patients with COVID-19. The IL-6 antagonists commonly investigated were monoclonal antibodies that bind either to membrane-bound and soluble IL-6 receptors (eg, tocilizumab and sarilumab) or directly to IL-6 (eg, siltuximab).5
To address the need for reliable efficacy data to guide clinical management, the World Health Organization (WHO) Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group developed a prospective meta-analysis protocol to perform a prospective meta-analysis of IL-6 antagonists in patients hospitalized for COVID-19. This approach was recently used6 to evaluate the use of corticosteroids in patients with COVID-19.7 During this initiative, trials variously reported potential clinical benefit,8,9,10 no benefit,11,12,13 and potential harm14 with IL-6 antagonists in patients hospitalized for COVID-19.
The primary objective of this prospective meta-analysis of randomized trials6 was to estimate the association between administration of IL-6 antagonists, compared with usual care or placebo, and mortality at 28 days after randomization in patients hospitalized for COVID-19. The secondary objectives were to estimate associations within subgroups relating to disease severity (eg, level of respiratory support), treatments at randomization (eg, receipt of corticosteroids), patient characteristics (eg, age), and risk of bias15 overall and separately for tocilizumab and sarilumab.
Methods
Identification and Eligibility of Trials
Trials were identified through systematic searches of ClinicalTrials.gov, the EU Clinical Trials Register, and the WHO International Clinical Trials Registry Platform from October 7, 2020, to January 11, 2021. The search terms used were random* AND COVID in the title or abstract, along with terms for common IL-6 antagonists individually (tocilizumab, sarilumab, clazakizumab, siltuximab, olokizumab) and the term interleukin 6. Individual searches were then combined. Searches were not restricted by trial status (ongoing or completed), publication status, or language. Additional trials were identified through contact with experts from the REACT Working Group. Queries regarding eligibility for inclusion were resolved by consensus. Eligible trials randomly assigned patients hospitalized for COVID-19 to IL-6 antagonists vs usual care or placebo. Trials in which anti–IL-6 therapies were combined with other immunomodulatory agents or with active comparators other than systemic corticosteroids were excluded.
Development of Prospective Meta-analysis Protocol
The WHO chief scientist invited investigators of eligible trials to participate in this prospective meta-analysis. Representative investigators and sponsors of potentially eligible trials were asked to participate in weekly development calls for the prospective meta-analysis protocol starting on November 23, 2020. The prospective meta-analysis protocol was registered on the PROSPERO database on January 14, 2021, and regularly updated. The PICO (patient problem or population, intervention, comparison or control, and outcome) framework, definitions of outcomes, and subgroups of interest were agreed upon prior to collection of outcome data.6 The final version of the prospective meta-analysis protocol was registered before analyses started on March 29, 2021.
Trial-level aggregate data sharing agreements were established. All trials had secured institutional review board approval, but approval was not required for secondary analyses. Informed consent for participation in each trial was obtained, consistent with local institutional review board requirements. Trial investigators were asked to complete baseline and outcome data collection forms that were subsequently verified by trial teams. Finalized data sets from contributing trials were received by May 11, 2021.
Outcomes and Comparisons
The primary outcome measure was all-cause mortality at 28 days after randomization. Two comparisons were specified a priori. The primary comparison investigated the class effect of IL-6 antagonists vs usual care or placebo and tocilizumab and sarilumab were examined separately. The second comparison was of IL-6 antagonists vs corticosteroids.
The secondary outcomes included: (1) invasive mechanical ventilation (IMV), extracorporeal membrane oxygenation (ECMO), or death by 28 days in patients not receiving IMV at randomization (this is the most important secondary outcome for which data on all subgroups were collected); (2) cardiovascular system support (defined as receipt of vasopressors) or death by 28 days in patients not receiving cardiovascular system support at randomization; (3) secondary infections by 28 days (this is the most important safety outcome); (4) in-hospital mortality; (5) kidney replacement therapy (KRT) or death by 28 days in patients not receiving KRT at randomization (excluding patients with underlying dialysis dependence or ≥stage III chronic kidney disease); (6) discharged alive from the hospital by 28 days; (7) mortality by 90 days; (8) duration of IMV up to 28 days (in those receiving IMV at randomization, with duration coded as 28 days for patients who died); and (9) secondary infections by 90 days. Data on serious adverse events or serious adverse reactions (as defined in each trial) were collected; however, no meta-analysis was planned because diverse definitions were used by different trials.
Subgroup Analyses
Trial investigators supplied summary data for all outcomes according to intervention group, overall, and in subgroups based on: (1) degree of respiratory support at randomization (patient not receiving supplemental oxygen therapy, patient receiving supplemental oxygen therapy [defined as oxygen flow rate ≤15 L/min by face mask or nasal cannula], patient receiving noninvasive ventilation [defined as oxygen flow rate >15 L/min, high-flow nasal cannula, continuous positive airway pressure], or patient receiving IMV or ECMO) and (2) receipt of systemic corticosteroids at randomization. In addition, the following subgroups were used for the outcomes of 28-day all-cause mortality and progression to IMV or death: (1) patients receiving acute organ support therapy at randomization (vasopressors or KRT) among those receiving noninvasive ventilation, IMV, or ECMO; (2) age (<70 years or ≥70 years); (3) sex (female or male); (4) race/ethnicity (collected by investigators in each individual trial); and (5) C-reactive protein level at baseline (categorized as <75, 75-<150, ≥150 μg/mL). The assigned dose of IL-6 antagonists was classified as low (4 mg/kg of tocilizumab; 200 mg of sarilumab) or high (>4 mg/kg of tocilizumab or multiple doses; >400 mg of sarilumab or multiple doses).
Risk of Bias Assessment
For each trial, the risk of bias (low risk, some concerns, or high risk) was assessed using version 2 of the Cochrane Risk of Bias Assessment Tool.15 Risk of bias assessments were based on the trial protocols and flowcharts following the Consolidated Standards of Reporting Trials together with information supplied by the investigators for each trial in a standard format. Risk of bias assessments were done independently by 3 of the investigators (J.P.T.H., F.S., J.S.) with disagreements resolved through discussion. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of the evidence.
Data Analyses
The primary analysis was an inverse variance–weighted fixed-effects meta-analysis of odds ratios (ORs). For the duration of IMV therapy, investigators supplied the mean difference and associated 95% CIs in days comparing the treatment and control groups. For the 90-day outcomes, the trial investigators were asked to estimate hazard ratios and 95% CIs (or log hazard ratios and associated standard errors) using Cox regression. Inconsistency in associations among the trials was quantified using the I2 statistic. P values for heterogeneity were derived using the Cochran Q statistic. Precise P values were reported; however, the prospective meta-analysis protocol specified that a threshold for statistical significance would not be used. As a sensitivity analysis for the primary outcome of 28-day all-cause mortality, overall associations also were estimated using random-effects meta-analyses with a restricted maximum likelihood estimate of heterogeneity16 and Hartung-Knapp adjustment17,18 to account for uncertainty in the estimation of between-study variance. To obtain illustrative absolute risk estimates for patients not receiving treatment with IL-6 antagonists, a mortality risk of 25% and a progression risk of 33% to IMV or death were assumed (the approximate risks among all eligible patients allocated to usual care or placebo). Meta-analytic ORs were then applied to obtain the corresponding risk with IL-6 antagonists. Because outcome data were generally complete or nearly complete across trials, we restricted the analyses to trial participants with outcomes recorded.
Differences in associations between the subgroups were quantified by calculating ratios of ORs (or analogous statistics for other outcome types) to compare the effects in the subgroups along with corresponding P values for interaction. If the ratio of ORs was equal to 1, the estimated associations in the 2 subgroups were the same. The further the ratio of ORs was from 1, the greater was the difference between the estimated associations in the 2 subgroups. Comparisons between subgroups defined by trial characteristics were made using random-effects meta-regression and appropriately accounted for common controls19 in trials with 3 treatment groups. Comparisons between subgroups defined by patient characteristics were done by estimating trial-specific ratios of ORs comparing associations between subgroups and then combining these in meta-analyses.20 The ORs in patients not receiving corticosteroids were compared with patients receiving corticosteroids at randomization within the respiratory support subgroups. Subgroup-specific estimates adjusted to correspond with the ratios of ORs that were derived from the within-trial approach were also estimated.
In the sensitivity analyses, associations were estimated that (1) excluded the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial; (2) restricted the analyses to trial results at low risk of bias; (3) restricted the analyses to trials published in peer-reviewed journals; (4) restricted the analyses to placebo-controlled trials; and (5) restricted the analyses to open-label trials. The first and third of these were post hoc sensitivity analyses. All analyses were conducted using Stata version 16 (StataCorp) and new Stata commands to conduct and graph the results of the meta-analyses.21,22
Results
A total of 72 potentially eligible trials were identified. After screening these trials, 38 ineligible trials, 3 duplicated records, and 2 trials directly comparing IL-6 antagonists with corticosteroids (NCT04329650 [n = 158 patients] and NCT04345445 [n = 59 patients]) were excluded. Of 29 eligible trials that randomized patients to receive IL-6 antagonists vs usual care or placebo, 1 trial (n = 50 patients) was unable to supply data in a timely manner and 1 trial (n = 295 patients) was still following up patients for the primary outcome.
Among the 27 trials included in the meta-analyses, 9 were published8,9,10,11,12,13,14,23,24 and the remaining 18 were unpublished or were reported as preprints (NCT04412772, NCT04331808 [there were 2 separate trials conducted under a common protocol], NCT04330638, NCT04479358, NCT04577534, NCT04435717, NCT04377750, NCT04409262, EU-CTR 2020-001748-24, EU-CTR 2020-001375-32, EU-CTR 2020-001442-19, NCT04324073 [there were 2 separate trials conducted under a common protocol], NCT04315298, NCT04357808, EU-CTR 2020-001531-27, and EU-CTR 2020-002037-15; Table 1 and eTables 1-3 in Supplement 1). Outcome data were supplied for 10 930 patients, representing 95.4% of all patients randomized in eligible trials (eFigure 1 in Supplement 1). Patients were recruited from 28 countries from February 26, 2020.
Table 1. Selected Characteristics of Included Trials.
Triala | Trial registration No. | Treatment groupb | No. of patients | Age, median (IQR), y | Concomitant therapy at randomization, No. (%) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oxygen flow rate ≤15 L/minc | Noninvasive ventilation | Invasive mechanical ventilation | Vasoactive medicationd | KRT | Remdesivir | Corticosteroidse | Convalescent plasma | Anticoagulant drugsf | |||||
Sarilumab | |||||||||||||
CORIMUNO-SARI (1) | NCT04324073 | Anti–IL-6 | 68 | 61.7 (53.0-71.1) | 68 (100) | 0 | 0 | 0 | 0 | 0 | 3 (4) | 0 | 41 (60) |
Usual care | 76 | 62.8 (56.0-71.7) | 76 (100) | 0 | 0 | 0 | 0 | 0 | 4 (5) | 0 | 38 (50) | ||
CORIMUNO-SARI (ICU) | NCT04324073 | Anti–IL-6 | 48 | 61.9 (53.8-66.2) | 0 | 16 (33) | 32 (67) | 0 | 0 | 0 | 0 | 0 | 26 (54) |
Usual care | 33 | 61.2 (55.3-68.5) | 0 | 9 (27) | 24 (73) | 0 | 0 | 0 | 2 (2) | 0 | 17 (52) | ||
Regeneron P2 | NCT04315298 | Anti–IL-6 (400 mg) | 180 | 56.5 (45.0-68.0) | 42 (23) | 45 (25) | 93 (52) | 53 (29) | 14 (8) | 0 | 28 (16) | 0 | 0 |
Anti–IL-6 (200 mg) | 187 | 60 (47.0-67.0) | 40 (21) | 41 (22) | 104 (56) | 58 (31) | 11 (6) | 0 | 34 (18) | 0 | 0 | ||
Placebo + usual care | 90 | 60 (52.0-69.0) | 28 (31) | 23 (26) | 39 (43) | 28 (31) | 3 (3) | 0 | 14 (16) | 0 | 0 | ||
Regeneron P3 | NCT04315298 | Anti–IL-6 (400 mg) | 567 | 63.0 (53.0-72.0) | 138 (24) | 206 (36) | 220 (39) | 99 (17) | 25 (4) | 0 | 194 (34) | 0 | 0 |
Anti–IL-6 (200 mg) | 477 | 60.0 (50.0-69.0) | 137 (29) | 144 (30) | 193 (40) | 94 (20) | 28 (6) | 0 | 151 (32) | 0 | 0 | ||
Placebo + usual care | 286 | 61.0 (50.0-71.0) | 78 (27) | 103 (36) | 104 (36) | 47 (16) | 8 (3) | 0 | 99 (35) | 0 | 0 | ||
REMAP-CAP | NCT02735707 | Anti–IL-6 | 48 | 64.5 (53-72.5) | 0 | 40 (83) | 8 (17) | 4 (8) | 0 | 15 (31) | 44 (92) | 0 | 0 |
Usual careg | 65 | 65 (53-71) | 0 | 57 (88) | 8 (12) | 1 (2) | 0 | 29 (46) | 52 (83) | 0 | 0 | ||
Sanofi | NCT04327388 | Anti–IL-6 (400 mg) | 173 | 58.0 (48.0-67.0) | 137 (79) | 11 (6) | 23 (13) | 6 (4) | 0 | 0 | 42 (24) | 0 | 0 |
Anti–IL-6 (200 mg) | 159 | 58.0 (51.0-67.0) | 123 (77) | 14 (11) | 16 (10) | 5 (3) | 2 (1) | 0 | 25 (16) | 0 | 0 | ||
Placebo + usual care | 84 | 60 (53.0-69.5) | 70 (83) | 5 (6) | 9 (11) | 1 (1) | 0 | 0 | 16 (19) | 0 | 0 | ||
SARCOVID | NCT04357808 | Anti–IL-6 | 20 | 61.5 (50.5-72) | 12 (60) | 4 (20) | 0 | 0 | 0 | 0 | 17 (85) | 0 | 19 (95) |
Control | 10 | 62 (58-71) | 10 (100) | 0 | 0 | 0 | 0 | 0 | 8 (80) | 0 | 10 (100) | ||
SARICOR | NCT04357860 | Anti–IL-6 (400 mg) | 39 | 57 (49-67) | 39 (100) | 0 | 0 | 0 | 0 | 7 (18) | 36 (92) | 0 | 39 (100) |
Anti–IL-6 (200 mg) | 37 | 66 (54-73) | 37 (100) | 0 | 0 | 0 | 0 | 3 (8) | 32 (86) | 0 | 37 (100) | ||
Usual care | 39 | 57 (51-71) | 39 (100) | 0 | 0 | 0 | 0 | 4 (10) | 39 (100) | 0 | 39 (100) | ||
SARTRE | EU-CTR 2020-002037-15 |
Anti–IL-6 | 70 | 58.8 (52-65) | 70 (100) | 0 | 0 | 0 | 0 | 1 (1) | 70 (100) | 0 | 0 |
Usual care | 70 | 58.0 (52-64) | 70 (100) | 0 | 0 | 0 | 0 | 1 (1) | 70 (100) | 0 | 0 | ||
Total | 2826 | 57-66h | 1214 (43) | 718 (25) | 873 (31) | 396 (14.0) | 91 (3) | 60 (2) | 980 (35) | 0 | 266 (9) | ||
Siltuximab | |||||||||||||
COV-AID (B) | NCT04330638 | Anti–IL-6 | 77 | 65.3 (54.3-71.4) | 41 (53) | 29 (38) | 5 (7) | 2 (3) | 0 | 2 (3) | 46 (60) | 0 | 68 (88) |
Usual carei | 72 | 63.3 (56.1-72.8) | 39 (54) | 23 (32) | 9 (13) | 4 (6) | 0 | 3 (4) | 42 (58) | 0 | 60 (83) | ||
Total | 149 | 64 | 80 (54) | 52 (35) | 14 (9) | 6 (4) | 0 | 5 (3) | 88 (59) | 0 | 128 (86) | ||
Tocilizumab | |||||||||||||
ARCHITECTS | NCT04412772 | Anti–IL-6 | 10 | 61.0 (46-67) | 0 | 0 | 10 (100) | 5 (50) | 2 (20) | 8 (80) | 9 (90) | 10 (100) | 7 (70) |
Placebo + usual care | 11 | 62.0 (54-71) | 1 (9) | 0 | 10 (91) | 7 (64) | 1 (9) | 11 (100) | 11 (100) | 11 (100) | 3 (37) | ||
BACC Bay | NCT04356937 | Anti–IL-6 | 161 | 61.6 (46.4-69.7) | 133 (83) | 5 (3) | 0 | 2 (1) | 0 | 34 (21) | 3 (2) | 0 | 0 |
Placebo + usual care | 82 | 56.5 (44.7-67.8) | 61 (74) | 5 (6) | 1 (1) | 1 (1) | 0 | 15 (18) | 1 (1) | 0 | 0 | ||
CORIMUNO-TOCI (1) | NCT04331808 | Anti–IL-6 | 63 | 64.0 (57.1-74.3) | 63 (100) | 0 | 0 | 0 | 0 | 0 | 10 (16) | 0 | 35 (56) |
Usual care | 67 | 63.3 (57.1-72.3) | 67 (100) | 0 | 0 | 0 | 0 | 0 | 12 (18) | 0 | 33 (49) | ||
CORIMUNO-TOCI (ICU) | NCT04331808 | Anti–IL-6 | 49 | 63.2 (59.4-70.9) | 0 | 13 (27) | 36 (73) | 0 | 0 | 0 | 8 (16) | 0 | 17 (35) |
Usual care | 43 | 65.4 (57.6-70.5) | 0 | 12 (28) | 31 (72) | 0 | 0 | 0 | 4 (9) | 0 | 14 (33) | ||
COVACTA | NCT04320615 | Anti–IL-6 | 294 | 63.0 (52.0-71.0) | 78 (27) | 94 (32) | 113 (38) | 77 (26) | 0 | 19 (6) | 36 (12) | 3 (1) | 0 |
Placebo + usual care | 144 | 61.5 (53.8-70.0) | 44 (31) | 39 (27) | 55 (38) | 38 (26) | 0 | 4 (3) | 33 (23) | 1 (1) | 0 | ||
COV-AID (A) | NCT04330638 | Anti–IL-6 | 81 | 62.4 (53.3-74.8) | 39 (48) | 32 (40) | 8 (10) | 5 (6) | 1 (1) | 6 (7) | 48 (59) | 0 | 73 (90) |
Usual carei | 72 | 63.3 (56.1-72.8) | 39 (54) | 23 (32) | 9 (13) | 4 (6) | 0 | 3 (4) | 42 (58) | 0 | 60 (83) | ||
COVIDOSE-2 (substudy A) | NCT04479358 | Anti–IL-6 (120 mg) | 10 | 65.0 (53-69) | 6 (60) | 0 | 0 | 0 | 1 (10) | 8 (80) | 3 (30) | 0 | 1 (10) |
Anti–IL-6 (40 mg) | 10 | 65.0 (54-68) | 5 (50) | 1 (10) | 0 | 0 | 0 | 7 (70) | 3 (30) | 0 | 4 (40) | ||
Usual care | 8 | 65.0 (55-68) | 4 (50) | 1 (13) | 0 | 0 | 0 | 5 (63) | 2 (25) | 0 | 2 (25) | ||
COVIDSTORM | NCT04577534 | Anti–IL-6 | 26 | 64.5 (15) | 15 (58) | 6 (23) | 0 | 0 | 0 | 0 | 17 (65) | 0 | 5 (19) |
Usual care | 13 | 68.0 (17) | 7 (54) | 4 (31) | 0 | 1 (8) | 0 | 0 | 13 (100) | 0 | 2 (15) | ||
COVINTOC | EU-CTR 2020/05/025369 |
Anti–IL-6 | 91 | 56.0 (47-63) | 48 (53) | 28 (31) | 5 (6) | 12 (13) | 0 | 14 (15) | 24 (26) | 0 | 87 (96) |
Usual care | 89 | 54.0 (43-63) | 56 (63) | 20 (23) | 4 (5) | 12 (13) | 0 | 13 (15) | 8 (9) | 0 | 86 (97) | ||
COVITOZ-01 | NCT04435717 | Anti–IL-6 (2 doses) | 7 | 56.0 (42-67) | 5 (57) | 0 | 0 | 0 | 0 | 2 (29) | 4 (57) | 0 | 5 (71) |
Anti–IL-6 (1 dose) | 10 | 58.0 (53-64) | 6 (60) | 0 | 0 | 0 | 0 | 3 (30) | 6 (60) | 0 | 9 (90) | ||
Usual care | 9 | 58.0 (47-62) | 6 (67) | 0 | 0 | 0 | 0 | 4 (44) | 7 (78) | 0 | 7 (78) | ||
EMPACTA | NCT04372186 | Anti–IL-6 | 249 | 57.0 (46-66) | 161 (64) | 64 (26) | 0 | 2 (1) | 3 (1) | 114 (46) | 174 (70) | 5 (2) | 228 (91) |
Placebo + usual care | 128 | 56.0 (45-65) | 81 (64) | 36 (28) | 0 | 4 (3) | 3 (2) | 62 (49) | 87 (69) | 1 (1) | 120 (95) | ||
HMO-0224-20 | NCT04377750 | Anti–IL-6 | 37 | 61.8 | 0 | 16 (43) | 21 (57) | 27 (73) | 4 (11) | 9 (24) | 31 (84) | 0 | 37 (100) |
Placebo + usual care | 17 | 65.8 | 0 | 5 (29) | 12 (71) | 12 (71) | 5 (29) | 3 (18) | 15 (88) | 0 | 17 (100) | ||
IMMCOVA | EU-CTR 2020-001748-24 |
Anti–IL-6 | 22 | 64.0 (56-70) | 10 (46) | 12 (55) | 0 | 1 (5) | 0 | 3 (14) | 21 (96) | 0 | 22 (100) |
Usual care | 27 | 62.0 (53-68) | 9 (33) | 18 (67) | 0 | 5 (19) | 0 | 4 (15) | 26 (96) | 0 | 27 (100) | ||
PRETOVID | EU-CTR 020-001375-32 |
Anti–IL-6 | 174 | 67 (60-74) | 125 (72) | 38 (22) | 2 (1) | 8 (5) | 0 | 36 (21) | 151 (87) | 0 | 0 |
Usual care | 180 | 66 (56-75) | 128 (71) | 43 (24) | 1 (<1) | 11 (6) | 0 | 29 (16) | 162 (90) | 0 | 0 | ||
RECOVERY | NCT04381936 | Anti–IL-6 | 2022 | 63.5 (54.2-73.6) | 931 (46) | 819 (41) | 268 (13) | 0 | 28 (1) | 544 (27) | 1664 (82) | 425 (21) | 1178 (58) |
Usual care | 2094 | 64.3 (55.0-73.9) | 928 (44) | 867 (41) | 294 (14) | 0 | 29 (1) | 573 (27) | 1721 (82) | 485 (23) | 1244 (59) | ||
REMAP-CAP | NCT02735707 | Anti–IL-6 | 353 | 61.0 (54-71) | 1 (<1) | 248 (70) | 104 (30) | 63 (18) | 0 | 72 (20) | 214 (61) | 0 | 0 |
Usual careg | 358 | 61.0 (53-70) | 2 (1) | 237 (66) | 119 (33) | 79 (22) | 2 (1) | 72 (21) | 217 (63) | 0 | 0 | ||
REMDACTA | NCT04409262 | Anti–IL-6 | 430 | 61.0 | 29 (7) | 336 (78) | 65 (15) | 0 | 0 | 83 (24) | 367 (85) | 0 | 0 |
Placebo + usual care | 210 | 59.0 | 13 (6) | 175 (83) | 22 (11) | 0 | 0 | 40 (19) | 184 (88) | 0 | 0 | ||
TOCIBRAS | NCT04403685 | Anti–IL-6 | 65 | 54.6 (44.2-70.2) | 39 (60) | 15 (23) | 11 (17) | 9 (14) | 0 | 0 | 45 (69) | 0 | 53 (82) |
Usual care | 64 | 57.9 (46.9-69.4) | 28 (44) | 26 (41) | 10 (16) | 7 (11) | 0 | 0 | 47 (73) | 0 | 54 (84) | ||
TOCOVID | NCT04332094 | Anti–IL-6 | 136 | 52.0 (44.0-60.5) | 74 (54) | 0 | 0 | 0 | 0 | 0 | 46 (34) | 0 | 123 (90) |
Usual care | 134 | 54.0 (42.0-60.0) | 81 (60) | 0 | 0 | 0 | 0 | 1 (1) | 45 (34) | 0 | 127 (95) | ||
Total | 8050 j | 52-68h | 3223 (40) | 3238 (40) | 1211 (15) | 382 (5) | 79 (1) | 1693 (21) | 5317 (66) | 941 (12) | 3860 (46) | ||
Anti–IL-6 vs corticosteroids k | |||||||||||||
STORM | NCT04345445 | Tocilizumab | 29 | 53.3 (14.84) | 65 (81) | 0 | 0 | 0 | 0 | 25 (31) | 5 (6) | 8 (10) | 0 |
Corticosteroids | 30 | 53.1 (20.97) | 62 (79) | 0 | 0 | 0 | 0 | 26 (33) | 4 (5) | 11 (14) | 0 | ||
SILCOR | NCT04329650 | Siltuximab | 80 | 61.33 (23.52) | 17 (59) | 1 (3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Corticosteroids | 78 | 62.70 (21.2) | 24 (80) | 4 (13) | 0 | 0 | 1 (3) | 0 | 1 (3) | 0 | 0 |
Abbreviations: IQR, interquartile range; KRT, kidney replacement therapy.
Additional trial characteristics appear in eTable 1 and eTable 2 in Supplement 1.
Control indicates use of placebo in blinded trials and usual care alone in open-label trials.
By face mask or nasal cannula.
Norepinephrine or epinephrine.
Dexamethasone, methylprednisolone, prednisolone, or hydrocortisone.
Heparin or low-molecular-weight heparin.
There were 21 patients in the usual care group for both treatment comparisons.
Expressed as range of medians.
Common control group across the COV-AID trial.
Baseline data but not outcome data supplied for 1 patient in the COVIDOSE substudy A and for 1 patient in the COVINTOC trial.
These trials were not included in the meta-analysis.
The IL-6 antagonists assessed were tocilizumab (19 trials allocating 4299 patients to tocilizumab and 3749 patients to usual care or placebo), sarilumab (9 trials allocating 2073 patients to sarilumab and 753 patients to usual care or placebo), and siltuximab (1 trial allocating 77 patients to siltuximab and 72 patients to usual care or placebo). The Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia8 (REMAP-CAP) and COV-AID (NCT04330638) trials randomized patients to more than 1 IL-6 antagonist. Due to limited data (including outcome events), associations for siltuximab within predefined subgroups were not estimated. Similarly, due to limited data, associations were not estimated in the predefined low-dose strata (2 trials for tocilizumab [27 patients] and in 2 trials for sarilumab [307 patients]), in the no oxygen respiratory support subgroup (27 patients and 4 deaths in 3 trials), and for trials reporting secondary infections at 90 days. Because of the diversity of classification of race/ethnicity among different trials, the subgroup analyses according to race/ethnicity are not reported. Because not all trials estimated hazard ratios for 90-day mortality, the event numbers were also analyzed to estimate the ORs.
The median age across the trials was 61 years (range of medians, 52-68 years) and 3560 patients (33%) were women. Concurrent treatments at randomization varied substantially among the trials. Most patients received respiratory support at randomization. A greater proportion of patients in the sarilumab trials received IMV (31% [873/3136 patients]) compared with patients in the tocilizumab trials (15% [1211/8134 patients]) and a smaller proportion received corticosteroids (35% [890/3136 patients] vs 66% [5317/8134 patients], respectively; Table 1). The primary outcome was missing for 183 patients (1.6%). Three trials recorded no deaths by 28 days (COVID-19: Salvage Tocilizumab as a Rescue Measure [COVIDSTORM {NCT04577534}; n = 39]; Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 [COVITOZ-01 {NCT04435717}; n = 26]; and Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection [COVID-19; TOCOVID] {NCT04332094} [n = 270]).
Risk of bias was assessed to be low in 22 of the trials contributing to the meta-analysis of 28-day all-cause mortality, comprising 78% of the weight in the analysis. Six trials were judged to have some concerns, mainly due to small numbers of patients being excluded from the data set because they did not receive their assigned intervention. In 1 trial judged as high risk, comprising 0.65% of the weight, the usual procedures were not in place to ensure that the allocation sequence was concealed; however, there was no reason to suspect that the concealed allocation was not implemented as intended. Risk of bias assessments were similar for progression to IMV or death. For secondary infections, results from open-label trials were judged to have some concerns over bias in determining whether such infections had occurred due to the subjective nature of the decision (eFigure 2 and eTable 4 in Supplement 1).
Association Between IL-6 Antagonists and 28-Day All-Cause Mortality
By 28 days after randomization, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo. Using a fixed-effects meta-analysis, the summary OR was 0.86 (95% CI, 0.79-0.95; P = .003). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The summary OR was 0.89 (95% CI, 0.76-1.05; P = .16) in a sensitivity analysis using random-effects meta-analysis (eFigure 3 in Supplement 1). The certainty in this result was assessed to be high in the GRADE assessment.
In 19 trials that randomized 4299 patients to tocilizumab (960 deaths) and 3749 patients to usual care or placebo (1023 deaths), the summary OR was 0.83 (95% CI, 0.74-0.92; P < .001). This corresponds to an absolute mortality risk of 22% for tocilizumab compared with an assumed mortality risk of 25% for usual care or placebo. In 9 trials that randomized 2073 patients to sarilumab (473 deaths) and 753 patients to usual care or placebo (139 deaths), the summary OR was 1.08 (95% CI, 0.86-1.36; P = .52). This corresponds to an absolute mortality risk of 26% for sarilumab compared with an assumed mortality risk of 25% for usual care or placebo. There was little inconsistency between the trial results (I2 = 18% overall, I2 = 3% for tocilizumab, and I2 = 0% for sarilumab). The inverse association with 28-day all-cause mortality appeared more marked for tocilizumab than for sarilumab (ratio of ORs, 0.76 [95% CI, 0.59-0.98], P = .04 for interaction; Figure 1 and Table 2).
Table 2. Subgroup Analysis of 3 Outcomes by Treatment Group and Respiratory Support, Organ Support, Age, Sex, and C-Reactive Protein Level.
Subgroup | All anti–IL-6 agents | Tocilizumab | Sarilumab | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of events/total patients | I2, % | OR (95% CI) | No. of events/total patients | I2, % | OR (95% CI) | No. of events/total patients | I2, % | OR (95% CI) | ||||
Anti–IL-6 | Control | Anti–IL-6 | Control | Anti–IL-6 | Control | |||||||
28-d mortality | ||||||||||||
Respiratory support at randomization | ||||||||||||
Oxygen flow rate ≤15 L/min | 277/2246 | 283/1708 | 0 | 0.81 (0.67-0.98) | 232/1622 | 256/1407 | 0 | 0.82 (0.67-1.00) | 41/583 | 27/301 | 0 | 0.74 (0.42-1.30) |
Noninvasive ventilation | 588/2209 | 544/1655 | 8 | 0.83 (0.72-0.96) | 463/1684 | 505/1479 | 0 | 0.80 (0.68-0.93) | 119/496 | 40/191 | 0 | 1.20 (0.78-1.84) |
IMV or ECMO | 496/1289 | 305/728 | 0 | 0.95 (0.78-1.16) | 250/634 | 244/559 | 6 | 0.92 (0.72-1.17) | 246/650 | 64/174 | 20 | 1.05 (0.74-1.50) |
Acute organ support at randomization | ||||||||||||
No cardiovascular system support | 123/616 | 135/501 | 14 | 0.68 (0.51-0.91) | 106/536 | 120/457 | 10 | 0.70 (0.51-0.94) | 11/48 | 18/64 | 0 | 0.66 (0.26-1.64) |
Cardiovascular system support | 70/196 | 59/153 | 17 | 0.89 (0.56-1.42) | 69/190 | 59/153 | 14 | 0.93 (0.58-1.47) | 1/4 | 1/1 | 0 | 0.14 (0.00-5.95) |
Age group, y | ||||||||||||
<70 | 674/4209 | 522/2931 | 0 | 0.89 (0.78-1.02) | 446/2864 | 456/2457 | 0 | 0.86 (0.74-0.99) | 225/1291 | 67/490 | 9 | 1.10 (0.80-1.52) |
≥70 | 703/1727 | 629/1310 | 17 | 0.82 (0.70-0.95) | 514/1254 | 567/1136 | 8 | 0.76 (0.64-0.89) | 182/450 | 65/179 | 0 | 1.17 (0.80-1.71) |
Sex | ||||||||||||
Female | 413/1933 | 311/1335 | 0 | 0.96(0.80-1.15) | 294/1365 | 270/1134 | 0 | 0.96 (0.79-1.17) | 117/553 | 43/209 | 0 | 0.95 (0.62-1.46) |
Male | 964/4003 | 840/2906 | 1 | 0.83 (0.74-0.93) | 666/2753 | 753/2459 | 0 | 0.78 (0.69-0.88) | 290/1188 | 89/460 | 0 | 1.17 (0.88-1.55) |
C-reactive protein level, μg/mLa | ||||||||||||
<75 | 83/710 | 57/429 | 0 | 0.84 (0.56-1.26) | 36/344 | 36/260 | 0 | 0.80 (0.46-1.39) | 46/354 | 21/171 | 0 | 0.89 (0.49-1.62) |
75-<150 | 451/1957 | 467/1635 | 3 | 0.79 (0.67-0.92) | 357/1484 | 435/1456 | 9 | 0.76 (0.65-0.90) | 90/438 | 33/184 | 0 | 1.01 (0.62-1.64) |
≥150 | 678/2366 | 490/1625 | 0 | 0.96 (0.83-1.11) | 427/1507 | 429/1365 | 0 | 0.91 (0.77-1.07) | 246/831 | 64/271 | 4 | 1.16 (0.83-1.62) |
Progression to IMV, EMCO, or death by 28 d | ||||||||||||
Respiratory support at randomization | ||||||||||||
Oxygen flow rate ≤15 L/min | 362/2266 | 396/1778 | 0 | 0.75 (0.64-0.89) | 299/1724 | 359/1505 | 0 | 0.72 (0.60-0.86) | 55/501 | 37/273 | 0 | 0.96 (0.60-1.53) |
Noninvasive ventilation | 856/2129 | 805/1636 | 14 | 0.77 (0.68-0.89) | 694/1690 | 750/1483 | 0 | 0.74 (0.64-0.85) | 145/410 | 60/168 | 0 | 1.06 (0.71-1.57) |
Acute organ support at randomization | ||||||||||||
No cardiovascular system support | 207/524 | 202/424 | 26 | 0.72 (0.55-0.95) | 173/451 | 183/382 | 2 | 0.70 (0.53-0.93) | NAb | NAb | NAb | NAb |
Cardiovascular system support | 12/16 | 8/15 | 0 | 1.58 (0.30-8.30) | 12/16 | 8/15 | 0 | 1.58 (0.30-8.30) | NAb | NAb | NAb | NAb |
Age group, y | ||||||||||||
<70 | 649/3160 | 622/2387 | 0 | 0.78 (0.68-0.89) | 523/2457 | 566/2079 | 0 | 0.76 (0.66-0.87) | 110/654 | 60/320 | 0 | 0.87 (0.60-1.27) |
≥70 | 577/1402 | 586/1137 | 0 | 0.75 (0.64-0.89) | 477/1112 | 548/1017 | 0 | 0.70 (0.59-0.84) | 91/267 | 39/123 | 0 | 1.20 (0.74-1.97) |
Sex | ||||||||||||
Female | 362/1526 | 334/1149 | 14 | 0.81 (0.68-0.98) | 300/1223 | 306/1014 | 14 | 0.80 (0.66-0.97) | 57/289 | 31/141 | 2 | 0.83 (0.48-1.44) |
Male | 864/3036 | 874/2375 | 7 | 0.75 (0.67-0.85) | 700/2346 | 808/2082 | 0 | 0.71 (0.63-0.81) | 144/632 | 68/302 | 0 | 1.08 (0.76-1.55) |
C-reactive protein level, μg/mLa | ||||||||||||
<75 | 87/687 | 77/443 | 0 | 0.74 (0.51-1.09) | 52/426 | 55/307 | 0 | 0.69 (0.43-1.12) | 33/250 | 23/138 | 0 | 0.83 (0.43-1.59) |
75-<150 | 453/1632 | 504/1450 | 0 | 0.76 (0.65-0.89) | 389/1335 | 481/1325 | 0 | 0.73 (0.62-0.87) | 54/265 | 23/129 | 0 | 1.14 (0.63-2.07) |
≥150 | 519/1595 | 492/1248 | 0 | 0.78 (0.67-0.92) | 407/1235 | 453/1109 | 0 | 0.74 (0.62-0.88) | 100/333 | 43/147 | 34 | 1.03 (0.65-1.63) |
Secondary infections to 28 d c | ||||||||||||
Respiratory support at baseline | ||||||||||||
Oxygen flow rate ≤15 L/min | 100/1244 | 60/789 | 1 | 1.06 (0.75-1.52) | 63/620 | 45/488 | 35 | 1.04 (0.68-1.60) | 34/583 | 15/301 | 0 | 1.06 (0.56-2.02) |
Noninvasive ventilation | 260/1052 | 122/487 | 0 | 0.96 (0.74-1.24) | 155/567 | 94/352 | 0 | 0.92 (0.67-1.26) | 99/456 | 28/135 | 0 | 1.01 (0.63-1.63) |
IMV or ECMO | 380/913 | 139/318 | 22 | 0.86 (0.65-1.15) | 134/266 | 76/151 | 23 | 0.76 (0.49-1.20) | 244/642 | 63/167 | 53 | 0.94 (0.65-1.34) |
Abbreviations: ECMO, extracorporeal membrane oxygenation; IMV, invasive mechanical ventilation; OR, odds ratio.
Normal level is less than 5 μg/mL.
Insufficient data to investigate the comparison of subgroups within trials.
Full results within extended subgroups were not collected for outcomes other than all-cause mortality and progression to IMV, ECMO, or death at 28 days.
Data on receipt of corticosteroids at randomization were available in 22 trials (9953 patients and 2495 deaths). The summary ORs for 28-day all-cause mortality comparing IL-6 antagonists with usual care or placebo were 1.09 (95% CI, 0.91-1.30) for 3637 patients (830 deaths) not receiving corticosteroids and 0.78 (95% CI, 0.69-0.88) for 6316 patients (1665 deaths) receiving corticosteroids (Figure 2). The corresponding absolute mortality risk in patients receiving corticosteroids was 21% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. Based on within-trial estimates combined across 17 trials that included patients receiving and not receiving corticosteroids, the inverse association between IL-6 antagonists and mortality was more marked in patients receiving corticosteroids (ratio of ORs, 0.72 [95% CI, 0.56-0.92]; P = .008 for interaction). The summary OR for the association with mortality for tocilizumab (15 trials, 7490 patients, and 1951 deaths) was 1.06 (95% CI, 0.85-1.33) in patients not receiving corticosteroids at randomization and was 0.77 (95% CI, 0.68-0.87) in patients receiving corticosteroids at randomization. The summary ratio of ORs (based on within-trial comparisons) was 0.69 (95% CI, 0.52-0.91; P = .008 for interaction). The corresponding summary ORs for sarilumab (8 trials, 2406 patients, and 538 deaths) were 1.18 (95% CI, 0.88-1.58) and 0.92 (95% CI, 0.61-1.38), respectively. The summary ratio of ORs (based on within-trial comparisons) was 0.77 (95% CI, 0.44-1.33; P = .34 for interaction). The corresponding absolute mortality risks in patients receiving corticosteroids were 20% for tocilizumab and 23% for sarilumab compared with an assumed mortality risk of 25% for usual care or placebo. In additional analyses, associations were compared in patients not receiving and receiving corticosteroids at randomization within the respiratory support subgroups. The tendency for more marked inverse associations among patients receiving corticosteroids appeared broadly consistent across respiratory support subgroups; however, the associations were not estimated precisely.
Detailed results, forest plots, and comparisons between subgroups for 28-day all-cause mortality appear in Supplements 1 and 2. Data on respiratory support at randomization were available in 21 trials (9835 patients and 2493 deaths). The summary ORs for 28-day all-cause mortality comparing IL-6 antagonists with usual care or placebo were 0.81 (95% CI, 0.67-0.98) in 3954 patients (560 deaths) receiving supplemental oxygen at randomization, 0.83 (95% CI, 0.72-0.96) in 3864 patients (1132 deaths) receiving noninvasive ventilation or high-flow nasal cannula at randomization, and 0.95 (95% CI, 0.78-1.16) in 2017 patients (801 deaths) receiving IMV or ECMO at randomization (P = .71 for the differences between associations across these subgroups; Table 2). The corresponding summary ORs for tocilizumab were 0.82 (95% CI, 0.67-1.00), 0.80 (95% CI, 0.68-0.93), and 0.92 (95% CI, 0.72-1.17), respectively (P = .43 for differences between subgroups) and the corresponding summary ORs for sarilumab were 0.74 (95% CI, 0.42-1.30), 1.20 (95% CI, 0.78-1.84), and 1.05 (95% CI, 0.74-1.50), respectively (P = .65 for differences between subgroups).
The associations between IL-6 antagonists and 28-day all-cause mortality within other subgroups defined by patient characteristics at randomization appeared consistent across all these subgroups (all P values for comparisons between subgroups were greater than .11; Table 2 and Supplement 2).
Association Between IL-6 Antagonists and Progression to IMV or Death
Among patients not requiring IMV at randomization (24 trials), 1236 of 4650 randomized to IL-6 antagonists and 1220 of 3609 randomized to usual care or placebo progressed to requiring IMV or ECMO or died within 28 days. Most of the data (87%) were from trials assessing tocilizumab. The summary ORs compared with usual care or placebo were 0.77 (95% CI, 0.70-0.85; P < .001) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.35) for sarilumab (Figure 3). The corresponding absolute risks of progression to IMV or death were 28% for all IL-6 antagonists, 27% for tocilizumab, and 33% for sarilumab compared with an assumed risk of 33% for usual care or placebo. There was little inconsistency between the trial results (I2 = 0% for each meta-analysis). The certainty in the overall result was assessed to be high in the GRADE assessment. The ratio of ORs comparing the associations for tocilizumab and sarilumab was 0.74 (95% CI, 0.54-1.01; P = .06 for interaction).
The summary ORs for progression to IMV or death were 0.96 (95% CI, 0.79-1.17) in 2545 patients (707 progressed) not receiving corticosteroids and 0.71 (95% CI, 0.63-0.80) in 5482 patients (1715 progressed) receiving corticosteroids (Figure 2). The corresponding absolute risk for progression to IMV or death in patients receiving corticosteroids was 26% for IL-6 antagonists compared with an assumed risk of 33% for usual care or placebo. The ratio of ORs comparing the associations in those receiving and not receiving corticosteroids was 0.78 (95% CI, 0.59-1.02; P = .07 for interaction based on within-trial estimates combined across trials). The corresponding summary ORs for tocilizumab (17 trials, 6608 patients, and 2104 progressed) were 0.95 (95% CI, 0.76-1.20) and 0.69 (95% CI, 0.61-0.78), respectively, and the corresponding ratio of ORs was 0.70 (95% CI, 0.52-0.94; P = .02 for interaction). The corresponding summary ORs for sarilumab (7 trials, 1362 patients, and 298 progressed) were 0.98 (95% CI, 0.67-1.44) and 1.08 (95% CI, 0.67-1.75), respectively, and the corresponding ratio of ORs was 1.41 (95% CI, 0.65-3.07; P = .38 for interaction). The corresponding absolute risks for progression to IMV or death in patients receiving corticosteroids were 25% for tocilizumab and 35% for sarilumab compared with an assumed risk of 33% for progression to IMV or death for usual care or placebo.
The summary ORs for progression to IMV or death comparing IL-6 antagonists with usual care or placebo were 0.75 (95% CI, 0.64-0.89) in 4044 patients (758 progressed) receiving supplemental oxygen at randomization and 0.77 (95% CI, 0.68-0.89) in 3765 patients (1661 progressed) receiving noninvasive ventilation or high-flow nasal cannula (P = .67 for differences between these associations; Table 2). The corresponding summary ORs for tocilizumab were 0.72 (95% CI, 0.60-0.86) and 0.74 (95% CI, 0.64-0.85), respectively (P = .92 for differences between subgroups) and the corresponding summary ORs for sarilumab were 0.96 (95% CI, 0.60-1.53) and 1.06 (95% CI, 0.71-1.57), respectively (P = .31 for differences between subgroups). The corresponding absolute risks for progression to IMV or death were 27% for all IL-6 antagonists, 27% for tocilizumab, and 33% for sarilumab compared with an assumed risk for progression to IMV or death of 33% for usual care or placebo.
The associations between IL-6 antagonists and progression to IMV or death within other subgroups defined by patient characteristics at randomization appeared consistent across all other subgroups (all P values for comparisons between subgroups were greater than .28; Table 2 and Supplement 3).
Association Between IL-6 Antagonists and Infections by 28 Days
Among the 22 trials that reported 28-day infection outcomes, 750 events occurred among 3428 patients randomized to IL-6 antagonists and 330 events occurred among 1787 patients randomized to usual care or placebo. The fixed-effect summary OR was 0.99 (95% CI, 0.85-1.16) and there was little inconsistency between the trial results (I2 = 0%, P = .49 for heterogeneity; Figure 3). The certainty in this result was assessed to be moderate in the GRADE assessment due to minor concerns over risk of bias (because of subjectivity in the outcome assessment) and minor concerns over imprecision (because of the result being compatible with a slightly lower or higher risk among those receiving IL-6 antagonists). The ORs were 0.95 (95% CI, 0.77-1.16) for tocilizumab and 1.03 (95% CI, 0.80-1.32) for sarilumab (Figure 4 and Table 2). The summary ORs within subgroups were close to 1. Data on 28-day secondary infections appear in Supplement 4.
Association Between IL-6 Antagonists and Other Secondary Outcomes
Data on in-hospital mortality were available from 19 trials. The summary ORs for in-hospital mortality comparing IL-6 antagonists with usual care or placebo were 0.80 (95% CI, 0.71-0.89) in 7261 patients (1848 deaths), with little inconsistency between trials (I2 = 0%) (Table 3). Most of the data (90.7%) were from 14 trials (6587 patients and 1741 deaths) assessing tocilizumab and the summary OR was 0.80 (95% CI, 0.71-0.90).
Table 3. Additional Outcomes With Analysis by Respiratory Support and Corticosteroid Use .
Outcome and patient group | All anti–IL-6 agents | Tocilizumab | Sarilumab | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of events/total patients | I2, % | OR (95% CI) | No. of events/total patients | I2, % | OR (95% CI) | No. of events/total patients | I2, % | OR (95% CI) | ||||
Anti–IL-6 | Control | Anti–IL-6 | Control | Anti–IL-6 | Control | |||||||
In-hospital mortality | ||||||||||||
All patients | 858/3727 | 990/3534 | 0 | 0.80 (0.71 to 0.89) | 800/3323 | 941/3264 | 0 | 0.80 (0.71 to 0.90) | 44/327 | 53/291 | 0 | 0.70 (0.44 to 1.12) |
Respiratory support at randomization | ||||||||||||
Oxygen flow rate ≤15 L/min | 218/1636 | 262/1471 | 0 | 0.75 (0.62 to 0.92) | 196/1369 | 241/1276 | 0 | 0.75 (0.61 to 0.93) | 18/226 | 21/195 | 0 | 0.72 (0.36 to 1.44) |
Noninvasive ventilation | 409/1283 | 463/1280 | 2 | 0.83 (0.71 to 0.99) | 387/1196 | 449/1232 | 0 | 0.83 (0.70 to 0.99) | 14/58 | 15/63 | 0 | 0.98 (0.40 to 2.40) |
IMV or ECMO | 214/500 | 245/508 | 0 | 0.81 (0.63 to 1.04) | 200/456 | 232/482 | 0 | 0.84 (0.65 to 1.10) | 12/39 | 16/31 | 0 | 0.42 (0.16 to 1.15) |
Corticosteroid use at randomization | ||||||||||||
No | 229/1005 | 226/870 | 20 | 0.94 (0.75 to 1.18) | 199/844 | 193/751 | 22 | 1.02 (0.80 to 1.29) | 28/130 | 34/121 | 0 | 0.67 (0.37 to 1.22) |
Yes | 613/2464 | 743/2414 | 0 | 0.75 (0.66 to 0.85) | 585/2221 | 728/2264 | 0 | 0.74 (0.65 to 0.85) | 16/197 | 18/168 | 0 | 0.81 (0.38 to 1.71) |
Progression to cardiovascular system support or death a | ||||||||||||
All patients | 344/1587 | 343/1199 | 0 | 0.71 (0.59 to 0.86) | 314/1447 | 316/1106 | 0 | 0.70 (0.57 to 0.85) | 30/140 | 39/113 | 0 | 0.80 (0.42 to 1.52) |
Respiratory support at randomization | ||||||||||||
Oxygen flow rate ≤15 L/min | 72/738 | 64/499 | 0 | 0.74 (0.51 to 1.07) | 64/650 | 60/450 | 0 | 0.71 (0.48 to 1.05) | 8/88 | 4/49 | 0 | 1.03 (0.31 to 3.44) |
Noninvasive ventilation | 192/519 | 209/438 | 8 | 0.65 (0.49 to 0.84) | 173/475 | 189/397 | 9 | 0.63 (0.48 to 0.84) | 19/44 | 30/56 | 0 | 0.64 (0.28 to 1.45) |
IMV or ECMO | 64/100 | 53/82 | 0 | 1.13 (0.57 to 2.26) | 61/96 | 51/80 | 0 | 1.18 (0.59 to 2.39) | 3/4 | 4/6 | 0 | 1.50 (0.09 to 25.39) |
Corticosteroid use at randomization | ||||||||||||
No | 143/652 | 123/423 | 0 | 0.80 (0.57 to 1.11) | 138/636 | 118/407 | 0 | 0.76 (0.54 to 1.07) | 5/16 | 6/18 | 0 | 1.81 (0.31 to 10.44) |
Yes | 185/841 | 205/687 | 0 | 0.67 (0.52 to 0.86) | 160/717 | 184/611 | 0 | 0.66 (0.50 to 0.86) | 24/124 | 32/93 | 0 | 0.71 (0.35 to 1.43) |
Progression to kidney replacement therapy or death b | ||||||||||||
All patients | 935/3653 | 1069/3351 | 14 | 0.79 (0.71 to 0.88) | 920/3586 | 1051/3298 | 14 | 0.79 (0.71 to 0.88) | 15/67 | 22/74 | 0 | 0.80 (0.36 to 1.76) |
Respiratory support at randomization | ||||||||||||
Oxygen flow rate ≤15 L/min | 234/1489 | 263/1288 | 25 | 0.79 (0.65 to 0.97) | 234/1477 | 263/1278 | 25 | 0.79 (0.65 to 0.97) | NAc | NAc | NAc | NAc |
Noninvasive ventilation | 439/1329 | 523/1298 | 29 | 0.76 (0.64 to 0.89) | 428/1286 | 507/1258 | 23 | 0.77 (0.65 to 0.91) | NAc | NAc | NAc | NAc |
IMV or ECMO | 247/492 | 263/470 | 0 | 0.88 (0.68 to 1.15) | 243/484 | 262/468 | 0 | 0.88 (0.68 to 1.15) | NAc | NAc | NAc | NAc |
Corticosteroid use at randomization | ||||||||||||
No | 261/959 | 239/732 | 0 | 0.98 (0.78 to 1.22) | 258/952 | 235/721 | 0 | 0.97 (0.78 to 1.22) | 3/7 | 5/13 | 0 | 1.55 (0.22 to 10.83) |
Yes | 661/2425 | 890/2363 | 2 | 0.74 (0.66 to 0.84) | 649/2365 | 796/2322 | 8 | 0.75 (0.66 to 0.85) | 12/60 | 16/59 | 0 | 0.79 (0.33 to 1.89) |
Proportion discharged alive from the hospital at 28 d | ||||||||||||
All patients | 4017/6432 | 2592/4472 | 16 | 1.22 (1.12 to 1.33) | 2736/4282 | 2127/3740 | 0 | 1.30 (1.18 to 1.43) | 1227/2073 | 478/753 | 0 | 0.95 (0.78 to 1.15) |
Respiratory support at randomization | ||||||||||||
Oxygen flow rate ≤15 L/min | 1923/2337 | 1371/1800 | 0 | 1.32 (1.12 to 1.55) | 1390/1713 | 1113/1499 | 0 | 1.40 (1.18 to 1.66) | 498/583 | 258/301 | 0 | 0.93 (0.60 to 1.43) |
Noninvasive ventilation | 1257/2215 | 820/1659 | 27 | 1.27 (1.11 to 1.45) | 964/1690 | 726/1483 | 26 | 1.30 (1.13 to 1.51) | 278/496 | 104/191 | 0 | 1.10 (0.77 to 1.56) |
IMV or ECMO | 351/1289 | 168/728 | 0 | 1.18 (0.94 to 1.48) | 172/634 | 125/559 | 0 | 1.24 (0.94 to 1.63) | 117/650 | 45/174 | 0 | 1.06 (0.72 to 1.57) |
Corticosteroid use at randomization | ||||||||||||
No | 1438/2458 | 780/1368 | 21 | 1.10 (0.95 to 1.27) | 832/1293 | 576/986 | 10 | 1.17 (0.97 to 1.42) | 580/1134 | 205/384 | 31 | 0.96 (0.75 to 1.22) |
Yes | 2240/3534 | 1665/2911 | 0 | 1.31 (1.18 to 1.46) | 1828/2881 | 1474/2646 | 0 | 1.36 (1.21 to 1.52) | 384/607 | 202/283 | 0 | 0.97 (0.68 to 1.38) |
90-d mortality (binary outcome) | ||||||||||||
All patients | 721/3039 | 383/1612 | 4 | 0.89 (0.76 to 1.04) | 265/1367 | 231/1073 | 10 | 0.85 (0.69 to 1.05) | 442/1595 | 156/560 | 0 | 0.92 (0.74 to 1.16) |
Respiratory support | ||||||||||||
Oxygen flow rate ≤15 L/min | 88/874 | 43/461 | 0 | 1.17 (0.78 to 1.74) | 38/388 | 23/277 | 0 | 1.20 (0.67 to 2.12) | 45/445 | 20/184 | 35 | 1.05 (0.59 to 1.87) |
Noninvasive ventilation | 252/1003 | 154/553 | 22 | 0.81 (0.63 to 1.04) | 110/478 | 102/377 | 32 | 0.77 (0.56 to 1.06) | 135/496 | 53/191 | 0 | 0.90 (0.61 to 1.33) |
IMV or ECMO | 382/954 | 175/410 | 0 | 0.88 (0.69 to 1.13) | 114/299 | 103/241 | 0 | 0.85 (0.59 to 1.22) | 266/650 | 75/174 | 27 | 0.91 (0.65 to 1.29) |
Corticosteroid use at randomization | ||||||||||||
No | 430/1744 | 188/783 | 0 | 0.97 (0.78 to 1.19) | 118/582 | 93/413 | 2 | 0.86 (0.62 to 1.20) | 310/1131 | 96/372 | 0 | 1.07 (0.81 to 1.41) |
Yes | 294/1138 | 185/665 | 0 | 0.84 (0.66 to 1.06) | 144/620 | 135/505 | 0 | 0.84 (0.63 to 1.13) | 138/472 | 53/178 | 0 | 0.81 (0.55 to 1.21) |
Duration of IMV d | ||||||||||||
All patients | 610 | 561 | 0 | −0.84 (−1.82 to 0.13)e | 565 | 535 | 0 | −0.76 (−1.76 to 0.24)e | 40 | 32 | 0 | −2.07 (−10.24 to 11.57)e |
Corticosteroid use at randomization | ||||||||||||
No | 304 | 218 | 0 | −1.12 (−2.61 to 0.38)e | 266 | 195 | 0 | −0.95 (−2.54 to 0.64)e | NAc | NAc | NAc | NAc |
Yes | 298 | 332 | 0 | −0.26 (−1.57 to 1.04)e | 291 | 330 | 0 | −0.23 (−1.55 to 1.08)e | NAc | NAc | NAc | NAc |
Abbreviations: ECMO, extracorporeal membrane oxygenation; IMV, invasive mechanical ventilation; NA, not available; OR, odds ratio.
Among patients who were not receiving cardiovascular system support at randomization.
Among patients who were not receiving kidney replacement therapy at randomization.
Insufficient data to investigate the comparison of subgroups within trials.
Among patients who required IMV at randomization.
Data are expressed as weighted mean difference (95% CI).
Among patients not requiring cardiovascular system support at randomization (15 trials), 344 of 1587 patients randomized to IL-6 antagonists and 343 of 1199 patients randomized to usual care or placebo progressed to requiring cardiovascular system support or death within 28 days. Most of the data (2553/2786 patients; 91.1%) were from 13 trials assessing tocilizumab. The summary ORs were 0.71 (95% CI, 0.59-0.86) for IL-6 antagonists and 0.70 (95% CI, 0.57-0.85) for tocilizumab. Among patients not requiring KRT at randomization (13 trials), 935 of 3653 patients randomized to IL-6 antagonists and 1069 of 3351 patients randomized to usual care progressed to requiring KRT or died within 28 days. The summary OR was 0.79 (95% CI, 0.71-0.88); most of the data (6884/7004 patients; 98.2%) were from 12 trials assessing tocilizumab.
Among 10 904 patients recruited to participate in 26 trials, 6609 were discharged alive by 28 days. The summary OR comparing IL-6 antagonists with usual care or placebo was 1.22 (95% CI, 1.12-1.33), favoring IL-6 antagonists. The corresponding ORs were 1.30 (95% CI, 1.18-1.43) for tocilizumab and 0.95 (95% CI, 0.79-1.15) for sarilumab.
Data were available for all-cause mortality at 90 days in 13 trials and at 60 days in 4 trials (1104 deaths among 4651 patients). Two trials reported no events. The summary OR comparing IL-6 antagonists with usual care or placebo was 0.89 (95% CI, 0.76-1.04). The corresponding ORs were 0.85 (95% CI, 0.69-1.05) for tocilizumab and 0.92 (95% CI, 0.74-1.16) for sarilumab. Additional survival analyses for all-cause mortality at 90 days are reported in eTable 5 in Supplement 1.
Among 1171 patients who were receiving IMV at randomization and were recruited to 9 trials, the weighted mean difference comparing IL-6 antagonists with usual care or placebo in the duration of IMV was −0.84 (95% CI, −1.82 to 0.13), favoring IL-6 antagonists. Most of the data were from 8 trials assessing tocilizumab (1101/1171 patients; 94.0%).
Table 3 and Supplements 5-10 provide detailed analyses comparing IL-6 antagonists with usual care or placebo overall and in predefined subgroups for all of the secondary outcomes. Although the associations appeared broadly consistent across subgroups, many were not estimated precisely.
Serious Adverse Events or Reactions
Data describing serious adverse events were supplied by 23 trials. Risks of serious adverse events were broadly similar for patients randomized to IL-6 antagonists and to usual care or placebo across all trials. Data on secondary infections at 90 days after randomization were limited (11 trials and 310 events) (eTable 6 in Supplement 1), but the risk of secondary infections by 28 days was similar in patients treated with IL-6 antagonists (750/3428; 21.9%) and in those treated with usual care or placebo (330/1787; 17.6%) (OR accounting for trial sample sizes, 0.99 [95% CI, 0.85-1.16]).
Additional Analyses
The results of the prespecified and post hoc sensitivity analyses for the outcomes of 28-day all-cause mortality; progression to IMV, ECMO, or death by 28 days; and secondary infections by 28 days appear in eTable 7 in Supplement 1. After excluding the large RECOVERY trial, the ORs comparing tocilizumab with usual care or placebo were 0.82 (95% CI, 0.68-0.98) for 28-day all-cause mortality and 0.71 (95% CI, 0.59-0.84) for progression to IMV or death within 28 days (consistent with the primary analyses). The ORs for the trials at low risk of bias were similar to the overall ORs. The ORs restricted to trials published in peer-reviewed journals were consistent with the overall ORs for tocilizumab but were imprecisely estimated for sarilumab because of exclusion of the largest trial. The ORs were similar for open-label and placebo-controlled trials; however, the association of sarilumab compared with usual care for secondary infections appeared more marked in open-label trials (1.97 [95% CI, 0.89-4.34]) than in placebo-controlled trials (0.96 [95% CI, 0.74-1.24]). Supplement 1 includes summary details for all of the sensitivity analyses. Supplements 2-10 include details of prespecified sensitivity analyses by risk of bias and blinding status. Further additional analyses for all outcomes within patients receiving and not receiving corticosteroids at randomization appear in Supplement 11. The baseline and outcome data collection forms appear in Supplement 12. The prospective meta-analysis protocol appears in Supplement 13.
Discussion
In this prospective meta-analysis based on 10 930 patients hospitalized for COVID-19 from 27 randomized clinical trials, administration of IL-6 antagonists was associated with lower all-cause mortality 28 days after randomization. Administration of IL-6 antagonists also was associated with lower progression to IMV or death, cardiovascular support or death, and KRT or death in patients not receiving support for the corresponding organ at randomization and with a greater probability of being discharged alive by 28 days. Administration of IL-6 antagonists was not associated with an increased risk of 28-day infection compared with usual care or placebo. There was no clear association between administration of IL-6 antagonists and all-cause mortality at 90 days or in the duration of IMV among patients who required IMV at randomization; however, the data were limited.
Among the a priori–defined subgroups, the association of IL-6 antagonists with improved outcomes appeared more marked among patients who were receiving corticosteroids at randomization compared with those who were not. The association of IL-6 antagonists with lower 28-day all-cause mortality was more marked among patients who did not require IMV at randomization, consistent with the inverse association of progression to IMV or death among these patients. However, these differences between subgroups may have arisen due to sampling variation. Associations appeared broadly consistent across patient subgroups according to levels of cardiovascular support, C-reactive protein level, age, and sex.
In general, associations with improved outcomes were more marked for tocilizumab than for sarilumab, although comparisons between tocilizumab and sarilumab were indirect (made between trials). However, the trials of sarilumab were generally done earlier in the pandemic than those of tocilizumab and before corticosteroids became the standard of care.7 The majority of patients in trials of sarilumab were not receiving corticosteroids at randomization, whereas the majority of patients in trials of tocilizumab were receiving corticosteroids at randomization. When comparisons were made within groups defined by receipt of corticosteroids at randomization, the differences between associations for these 2 IL-6 antagonists were less marked. Nearly 3 times as many patients were randomized to trials comparing tocilizumab with usual care or placebo compared with trials comparing sarilumab with usual care or placebo. For this reason, associations were estimated more precisely for tocilizumab than for sarilumab. Both drugs were IL-6 receptor antagonists, but there may be differences between tocilizumab and sarilumab in receptor binding or lung concentrations.25 Concurrent administration of IL-6 antagonists5 and corticosteroids,26 which both have anti-inflammatory effects, may provide greater improvement than either type of drug given individually.8,9
This prospective meta-analysis included an estimated 97% of patients randomized to IL-6 receptor antagonists vs usual care worldwide. Because data were shared based on standardized definitions of outcomes and subgroups agreed upon in advance, these aggregate data meta-analyses had many of the advantages of individual-patient data meta-analyses while avoiding the need to establish formal data sharing agreements. The methods used in this meta-analysis limit bias in the selection and appraisal of trials with prespecified subgroup analyses based on clinically relevant questions. For tocilizumab, the results from other trials were similar to those from the large RECOVERY trial, supporting generalizability of the findings across settings.
Limitations
This study has several limitations. First, some of the included trials are ongoing and have not been published in peer-reviewed journals. It is possible that lack of participation or participation by some of the ongoing trials may be based on knowledge of their interim results. This limitation was addressed in the sensitivity analyses and the results were consistent with the primary analyses.
Second, there were limited data for some comparisons and questions of interest such as IL-6 antagonists vs corticosteroids and the effect of siltuximab. Third, potential differences in treatment effect by differences in the baseline risk of death (eg, that arose either from trial-specific eligibility criteria, geographic differences, or improving trends in the outcomes of patients with COVID-19 during the pandemic) could not be accounted for.
Fourth, the definitions and reporting of serious adverse events were not consistent across the trials and therefore a meta-analysis for this secondary end point was not conducted. Fifth, larger trials were mainly conducted in high-income settings; 65.9% of the tocilizumab data were provided by participants in the RECOVERY trial9 and 71.0% of the sarilumab data were provided by participants in the Regeneron trial (NCT04315298).
Conclusions
In this prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.
References
- 1.Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Laing AG, Lorenc A, Del Molino Del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26(10):1623-1635. doi: 10.1038/s41591-020-1038-6 [DOI] [PubMed] [Google Scholar]
- 3.Mathew D, Giles JR, Baxter AE, et al. ; UPenn COVID Processing Unit . Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511. doi: 10.1126/science.abc8511 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Marshall JC, Murthy S, Diaz J, et al. ; WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection . A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021;9(6):643-654. doi: 10.1016/S2213-2600(21)00103-X [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tierney JF, Fisher DJ, Vale CL, et al. A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. PLoS Med. 2021;18(5):e1003629. doi: 10.1371/journal.pmed.1003629 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sterne JAC, Murthy S, Diaz JV, et al. ; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group . Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341. doi: 10.1001/jama.2020.17023 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Gordon AC, Mouncey PR, Al-Beidh F, et al. ; REMAP-CAP Investigators . Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502. doi: 10.1056/NEJMoa2100433 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Abani O, Abbas A, Abbas F, et al. ; RECOVERY Collaborative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group . Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503-1516. doi: 10.1056/NEJMoa2028700 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20-30. doi: 10.1056/NEJMoa2030340 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Stone JH, Frigault MJ, Serling-Boyd NJ, et al. ; BACC Bay Tocilizumab Trial Investigators . Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. doi: 10.1056/NEJMoa2028836 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Veiga VC, Prats JAGG, Farias DLC, et al. ; Coalition COVID-19 Brazil VI Investigators . Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372(n84):n84. doi: 10.1136/bmj.n84 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898 [DOI] [PubMed] [Google Scholar]
- 16.Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. 2019;10(1):83-98. doi: 10.1002/jrsm.1316 [DOI] [PubMed] [Google Scholar]
- 17.Nikolakopoulou A, Mavridis D, Salanti G. Demystifying fixed and random effects meta-analysis. Evid Based Ment Health. 2014;17(2):53-57. doi: 10.1136/eb-2014-101795 [DOI] [PubMed] [Google Scholar]
- 18.Serghiou S, Goodman SN. Random-effects meta-analysis: summarizing evidence with caveats. JAMA. 2019;321(3):301-302. doi: 10.1001/jama.2018.19684 [DOI] [PubMed] [Google Scholar]
- 19.Rücker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise meta-analysis. Res Synth Methods. 2017;8(4):392-403. doi: 10.1002/jrsm.1259 [DOI] [PubMed] [Google Scholar]
- 20.Fisher DJ, Carpenter JR, Morris TP, Freeman SC, Tierney JF. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? BMJ. 2017;356:j573. doi: 10.1136/bmj.j573 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.White IR. Network meta-analysis. Stata J. 2015;15(4):951-985. doi: 10.1177/1536867X1501500403 [DOI] [Google Scholar]
- 22.Fisher DJ. Two-stage individual participant data meta-analysis and generalized forest plots. Stata J. 2015;15(2):369-396. doi: 10.1177/1536867X1501500203 [DOI] [Google Scholar]
- 23.Lescure FX, Honda H, Fowler RA, et al. ; Sarilumab COVID-19 Global Study Group . Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):522-532. doi: 10.1016/S2213-2600(21)00099-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):511-521. doi: 10.1016/S2213-2600(21)00081-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Xu C, Rafique A, Potocky T, et al. Differential binding of sarilumab and tocilizumab to IL-6Rα and effects of receptor occupancy on clinical parameters. J Clin Pharmacol. 2021;61(5):714-724. doi: 10.1002/jcph.1795 [DOI] [PubMed] [Google Scholar]
- 26.Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723. doi: 10.1056/NEJMra050541 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.